Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) (tnAcity)

19. Februar 2019 aktualisiert von: Celgene

A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer

The purpose of this study is to compare the safety and efficacy of nab-paclitaxel in combination with either gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line treatment in female subjects with triple negative metastatic breast cancer (TNMBC) or metastatic triple negative breast cancer.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

ABI-007-MBC- 001 is a Phase 2/3, multicenter, open-label, randomized, study that will compare the safety and efficacy of weekly nab-paclitaxel in combination with gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line therapy in female subjects with Estrogen Receptor (ER), Progesterone Receptor (PgR), and human epidermal growth factor receptor 2 (HER2) negative (triple negative) metastatic breast cancer (TNMBC) or metastatic triple negative breast cancer. In the phase 2 portion of the study, the combinations of nab-paclitaxel plus gemcitabine and nab-paclitaxel plus carboplatin will be evaluated, and a comparator arm of gemcitabine combined with carboplatin will be used. In the phase 3 portion of the study, the selected nab-paclitaxel combination treatment will be compared to gemcitabine combined with carboplatin to evaluate progression free survival, safety and tolerability, overall survival, disease control rate and duration of response in women with metastatic triple negative breast cancer.

Due to changes in the treatment landscape since the initiation of this trial, the decision was made not to proceed to the Phase 3 portion of the study.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

191

Phase

  • Phase 2
  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Australien
      • Nedlands, Australien, 6009
        • Sir Charles Gairdner Hospital
    • Australian Capital Territory
      • Garran, Australian Capital Territory, Australien, 2605
        • Canberra Hospital
    • Victoria
      • Frankston, Victoria, Australien, 3199
        • Frankston Hospital Oncology Research
      • Wodonga, Victoria, Australien, 3690
        • Border Medical Oncology
  • Brasilien
      • Fortaleza, Brasilien, 60160-230
        • ONCOCLINIC Clinica de Oncologia LTDA
      • Ribeirao Preto, Brasilien, 14015-130
        • Instituto Ribeiraopretano de Combate Ao Cancer
      • Ribeirao Preto, Brasilien, 14048-900
        • Hospital das Clínicas da Faculdade de Medicina da USP
      • Rio Grande Do Sul, Brasilien, 95900-000
        • Hospital Bruno Born
      • Sao Jose Do Rio Preto, Brasilien, 15090-000
        • Hospital de Base Da Faculdade de Medicina de
      • Sao Paulo, Brasilien, 05651-901
        • Hospital Albert Einstein Sociedade Beneficente Israelita Brasileira
      • São Paulo, Brasilien, 01308-050
        • Sociedade Beneficente de Senhoras Hospital Sirio Libanes
      • São Paulo, Brasilien, 03102-002
        • Instituto Brasileiro de Controle do Cancer Ibcc
    • Bahia
      • Salvador, Bahia, Brasilien, 41820-021
        • Centro de Oncologia da Bahia
    • Paraná
      • Curitiba, Paraná, Brasilien, 81520-060
        • Liga Paranaense de Combate ao Cancer
    • Rio De Janeiro
      • Rio De Janerio, Rio De Janeiro, Brasilien, 20560-120
        • Instituto Nacional de Cancer - INCa
    • Rio Grande Do Sul
      • Porto Alegre, Rio Grande Do Sul, Brasilien, 90035-001
        • Associacao Hospitalar Moinhos de Vento Hospital Moinhos de Vento
      • Porto Alegre, Rio Grande Do Sul, Brasilien, 90610-000
        • Hospital Sao Lucas - PUCRS
    • São Paulo
      • Barretos, São Paulo, Brasilien, 14784-400
        • Fundacao Pio XII - Hospital de Cancer de Barretos
      • Jau/SP, São Paulo, Brasilien, 17210-080
        • Hospital Dr. Amaral Carvalho/ Hospital Amaral Carvalho Jaú
  • Deutschland
      • Berlin, Deutschland, 10713
        • Sankt Gertrauden-Krankenhaus
      • Bonn, Deutschland, 53111
        • Facharztpraxis fur Gynakologie und Geburtshilfe
      • Frankfurt, Deutschland, 60431
        • Agaplesion Markus Krankenhaus
      • Freiburg, Deutschland, 79110
        • Praxis für interdisziplinäre Onkologie & Hämatologie
      • Heidelberg, Deutschland, 69120
        • Universitaetsklinikum Heidelberg
      • Hildesheim, Deutschland, 31134
        • Frauenärzte am Bahnhofsplatz
      • Köln, Deutschland, 50679
        • Schwerpunktpraxis fur Gynakologische Onkologie
      • München, Deutschland, 81377
        • LMU Klinikum der Universität
      • Trier, Deutschland, 54290
        • Krankenanstalt Mutterhaus der Borromaerinnen
      • Ulm, Deutschland, 89075
        • Universitätsklinikum Ulm
  • Frankreich
      • Clermont-Ferrand, Frankreich, 63003
        • Centre Jean PERRIN
  • Griechenland
      • Athens, Griechenland, 11528
        • University of Athens Medical school - Regional General Hospital
      • Athens, Griechenland, 15562
        • IASO General
      • Faliro, Griechenland, 18547
        • Metropolitan Hospital
      • Heraklion, Griechenland, 71110
        • University General Hospital of Heraklion
      • Rio Patras, Griechenland, 26500
        • University General Hospital of Patras
  • Italien
      • Bologna, Emilia-Romagna, Italien, 40138
        • Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi
      • Ferrara, Italien, 44124
        • Azienda Ospedaliero-Universitaria di Ferrara Arcispedale Sant' Anna
      • Genova, Italien, 16132
        • IRCCS AziendaOspedaliera Universitaria San Martino
      • Grosseto, Italien, 58100
        • Presidio Ospedaliero della Misericordia
      • Messina, Italien, 98158
        • Azienda Ospedaliera Ospedali Riuniti Papardo-Piemonte
      • Monza, Italien, 20900
        • Azienda Ospedaliera San Gerardo
      • Napoli, Campania, Italien, 80131
        • Azienda Ospedaliera Universitaria Federico II
      • Napoli, Campania, Italien, 80131
        • Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale
      • Padova, Italien, 35128
        • Istituto Oncologico Veneto
      • Reggio Emilia, Italien, 42100
        • Arcispedale Santa Maria Nuova
      • Roma, Italien, 00189
        • Azienda Ospedaliera Sant Andrea
      • Roma, Italien, 144
        • Istituto Nazionale Tumori Regina Elena
      • Roma, Italien, 00168
        • Policlinico Universitario A Gemelli
      • Rozzano (MI), Italien, 20089
        • Istituto Clinico Humanitas
      • Torino, Piemonte, Italien, 10126
        • Azienda Ospedaliera Citta Della Salute E Della Scienza Di Torino
      • Treviglio, Italien, 24047
        • Azienda Ospedaliera Treviglio-Caravaggio
  • Kanada
    • Ontario
      • Ottawa, Ontario, Kanada, K1H 8L6
        • Ottawa General Hospital
    • Quebec
      • Montreal, Quebec, Kanada, H2L 4M1
        • CHUM - Notre Dame
      • Quebec City, Quebec, Kanada, G1S4L8
        • Hospital du Saint Scarement Sacrement Laboratory
      • Rimouski, Quebec, Kanada, G5L5T1
        • CSSS de Rimouski Neigette
    • Saskatchewan
      • Regina, Saskatchewan, Kanada, S4T1A5
        • Alan Blair Cancer Centre at Pasqua Hosptial
  • Portugal
      • Evora, Portugal, 7000-811
        • Hospital Espírito Santo
      • Lisboa, Portugal, 1500-650
        • Hospital da Luz
      • Lisboa, Portugal, 1649-035
        • Hospital de Santa Maria
      • Porto, Portugal, 4200-072
        • Instituto Portugues de Oncologia do Porto, Francisco Gentil
  • Spanien
      • Barcelona, Spanien, 08036
        • Clinic Barcelona Hospital Universitari
      • Barcelona, Spanien, 8035
        • Hospital Universitario Vall d Hebron
      • Cordoba, Spanien, 14004
        • Hospital Universitario Reina Sofia
      • Madrid, Spanien, 28007
        • Hospital General Gregorio Marañón
      • San Sebastian, Spanien, 20014
        • Onkologikoa - Kutxaren Institutu Onkologikoa
      • Santiago de Compostela, Spanien, 15706
        • Hospital Clínico Universitario de Santiago
      • Sevilla, Spanien, 41071
        • Hospital Universitario Virgen Macarena
      • Zaragoza, Spanien, 50009
        • Hospital Universitario Miguel Servet
  • Vereinigte Staaten
    • Arizona
      • Chandler, Arizona, Vereinigte Staaten, 85224
        • Ironwood Cancer and Research Center
      • Glendale, Arizona, Vereinigte Staaten, 85306
        • Arizona Center for Cancer Care
      • Scottsdale, Arizona, Vereinigte Staaten, 85259
        • Mayo Clinic Arizona
      • Scottsdale, Arizona, Vereinigte Staaten, 85251
        • Arizona Cancer Research Alliance
    • Arkansas
      • Fayetteville, Arkansas, Vereinigte Staaten, 72703
        • Highlands Oncology Group
    • California
      • Anaheim, California, Vereinigte Staaten, 92801
        • Pacific Cancer Medical Center INC
      • Escondido, California, Vereinigte Staaten, 92025
        • California Cancer Associates for Research and Excellence cCARE
      • La Jolla, California, Vereinigte Staaten, 92093
        • University of California San Diego Moores Cancer Center
      • La Verne, California, Vereinigte Staaten, 91750
        • Wilshire Oncology Medical Group, Inc
      • Los Angeles, California, Vereinigte Staaten, 90045
        • Translational Research Management
      • San Luis Obispo, California, Vereinigte Staaten, 93401
        • Coastal Integrative Cancer Care
      • Santa Maria, California, Vereinigte Staaten, 93454
        • Central Coast Medical Oncology Corporation
      • Santa Rosa, California, Vereinigte Staaten, 95403
        • Redwood Regional Medical Group, INC
    • Florida
      • Boca Raton, Florida, Vereinigte Staaten, 33486
        • Center for Hematology-Oncology
      • Hollywood, Florida, Vereinigte Staaten, 33021
        • Memorial Breast Cancer Center
      • Jacksonville, Florida, Vereinigte Staaten, 32224
        • Mayo Clinic - Jacksonville
      • Miami, Florida, Vereinigte Staaten, 33136
        • University of Miami School of Medicine
      • Saint Petersburg, Florida, Vereinigte Staaten, 33705
        • Florida Cancer Specialists
      • Sarasota, Florida, Vereinigte Staaten, 34232
        • Florida Cancer Specialists
      • West Palm Beach, Florida, Vereinigte Staaten, 33401
        • Florida Cancer Specialists
    • Illinois
      • Joliet, Illinois, Vereinigte Staaten, 60435
        • Joliet Oncology-Hematology Associates, LTD
      • Urbana, Illinois, Vereinigte Staaten, 61801
        • Carle Cancer Center
    • Indiana
      • Indianapolis, Indiana, Vereinigte Staaten, 46254
        • Investigative Clinical Research of Indiana, LLC
    • Louisiana
      • Lafayette, Louisiana, Vereinigte Staaten, 70503
        • University of South Alabama Mitchell Cancer Institute
    • Maryland
      • Baltimore, Maryland, Vereinigte Staaten, 21201
        • University of Maryland School of Med
      • Bethesda, Maryland, Vereinigte Staaten, 20817
        • Center for Cancer and Blood Disorders, PC
    • Michigan
      • Detroit, Michigan, Vereinigte Staaten, 48202-268
        • Henry Ford Medical Center - New Center One
    • Minnesota
      • Minneapolis, Minnesota, Vereinigte Staaten, 55407
        • Minnesota Oncology Hematology, PA
      • Rochester, Minnesota, Vereinigte Staaten, 55905
        • Mayo Clinic
    • Missouri
      • Kansas City, Missouri, Vereinigte Staaten, 64132
        • Midwest Physicians Group
      • Saint Louis, Missouri, Vereinigte Staaten, 63131
        • Missouri Baptist Medical Center
    • New Hampshire
      • Hooksett, New Hampshire, Vereinigte Staaten, 03106
        • New Hampshire Oncology Hematology
      • Lebanon, New Hampshire, Vereinigte Staaten, 03756
        • Dartmouth Hitchcock Medical Center Norris Cotton Cancer Center
    • New Jersey
      • Englewood, New Jersey, Vereinigte Staaten, 07631
        • Englewood Hospital and Medical Center
    • New York
      • East Syracuse, New York, Vereinigte Staaten, 13057
        • Hematology Oncology Associates of CNY
      • Lake Success, New York, Vereinigte Staaten, 11042
        • NYU Langone Arena Oncology
      • New York, New York, Vereinigte Staaten, 10021
        • Clinical Research Alliance
    • North Carolina
      • Burlington, North Carolina, Vereinigte Staaten, 27215-8700
        • Alamance Regional Medical Cancer Center
    • Ohio
      • Cincinnati, Ohio, Vereinigte Staaten, 45242
        • Oncology Hematology Care
      • Cincinnati, Ohio, Vereinigte Staaten, 45219
        • University of Cincinnatti
      • Columbus, Ohio, Vereinigte Staaten, 43219
        • Mark H Zangmeister Center
      • Toledo, Ohio, Vereinigte Staaten, 43623
        • Toledo Community Oncology Program
    • Oklahoma
      • Lawton, Oklahoma, Vereinigte Staaten, 73505
        • Cancer Centers of Southwest Oklahoma
    • Oregon
      • Coos Bay, Oregon, Vereinigte Staaten, 97420
        • North Bend Medical Center
      • Portland, Oregon, Vereinigte Staaten, 97213
        • Providence Portland Medical Center
      • Portland, Oregon, Vereinigte Staaten, 97213
        • Northwest Cancer Specialists, P.C. - Hoyt
    • Pennsylvania
      • Langhorne, Pennsylvania, Vereinigte Staaten, 19047
        • St Mary Medical Center
      • Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213
        • Magee Women's Hospital
    • South Carolina
      • Columbia, South Carolina, Vereinigte Staaten, 29210
        • South Carolina Oncology Associates
    • Tennessee
      • Chattanooga, Tennessee, Vereinigte Staaten, 37404
        • Chattanooga Oncology Hematology Associates
      • Nashville, Tennessee, Vereinigte Staaten, 37203
        • Sarah Cannon Cancer Center
    • Texas
      • Dallas, Texas, Vereinigte Staaten, 75231
        • Texas Oncology, PA
      • Dallas, Texas, Vereinigte Staaten, 75246
        • Texas Oncology, PA- Dallas
      • Fort Worth, Texas, Vereinigte Staaten, 76104
        • The Center for Cancer and Blood Disorders
      • Houston, Texas, Vereinigte Staaten, 77030
        • UT Physicians General Medicine
      • San Antonio, Texas, Vereinigte Staaten, 78217
        • Cancer Care Centers of South Texas - Loop
      • Tyler, Texas, Vereinigte Staaten, 75702
        • Texas Oncology P.A.- Tyler
    • Virginia
      • Fredericksburg, Virginia, Vereinigte Staaten, 22408
        • Hematology Oncology Associates of Fredericksburg
      • Portsmouth, Virginia, Vereinigte Staaten, 23704
        • Delta Hematologyoncology Associates
      • Richmond, Virginia, Vereinigte Staaten, 23230
        • Virginia Cancer Institute
    • Washington
      • Spokane, Washington, Vereinigte Staaten, 99208
        • Medical Oncology Associates
    • West Virginia
      • Huntington, West Virginia, Vereinigte Staaten, 25701
        • Edwards Comprehensive Cancer Center
    • Wisconsin
      • Green Bay, Wisconsin, Vereinigte Staaten, 54301
        • Saint Vincent Hospital
      • Milwaukee, Wisconsin, Vereinigte Staaten, 53211
        • Columbia St Marys Cancer Center
  • Vereinigtes Königreich
      • Bath, Vereinigtes Königreich, BA1 3NG
        • Royal United Hospital
      • London, Vereinigtes Königreich, W1G 6AD
        • Sarah Cannon Research Institute UK
      • Manchester, Vereinigtes Königreich, M20 4BX
        • The Christie NHS Foundation Trust
      • Middlesex, Vereinigtes Königreich, HA62RN
        • The East and North Hertfordshire NHS Trust
      • Sheffield South Yorkshire, Vereinigtes Königreich, S10 2SJ
        • Sheffield Teaching Hospitals NHS Foundation Trust
  • Österreich
      • Innsbruck, Österreich, 6020
        • Universitaetsklinik Innsbruck
      • Salzburg, Österreich, 5020
        • Salzburger Landkliniken St. Johanns-Spital
      • Vienna, Österreich, 1090
        • Medizinische Universität Wien

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria: A subject will be eligible for inclusion in this study only if all of the following criteria are met:

  1. Female subjects, age ≥ 18 years at the time informed consent is signed
  2. Pathologically confirmed adenocarcinoma of the breast

  3. Pathologically confirmed as triple negative, source documented, defined as both of the following

    1. Estrogen Receptor (ER) and Progesterone Receptor (PgR) negative: < 1% of tumor cell nuclei are immunoreactive in the presence of evidence that the sample can express ER or PgR (positive intrinsic controls)
    2. Human Epidermal Growth Factor Receptor 2 (HER2) negative as per American Society of Clinical Oncology - College of American Pathologists (ASCO/CAP) guidelines i. Immunohistochemistry (IHC) 0 or 1 Fluorescence In Situ Hybridization (FISH) negative (or equivalent negative test). Subjects with IHC 2 must have a negative by Fluorescence In Situ Hybridization (FISH),, (or equivalent negative test).
  4. Subjects with prior breast cancer history of different phenotypes (ie, ER/PgR/HER2 positive) must have pathologic confirmation of triple negative disease in at least one of the current sites of metastasis

  5. Subjects must have received prior adjuvant or neoadjuvant anthracycline therapy; unless (a) anthracycline treatment was not indicated or was not the best treatment option for the subject in the opinion of the treating physician; and (b) anthracycline treatment remains not indicated or, in the opinion of the treating physician, is not the best treatment option for the subject's metastatic disease.

    a. Newly diagnosed subjects presenting with TNMBC are eligible for the study if anthracycline treatment is not indicated or is not the best treatment option for the subject in the opinion of the treating physician.

  6. Subjects with measurable metastatic disease, defined by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) guidelines
  7. Life expectancy ≥ 16 weeks from randomization
  8. No prior cytotoxic chemotherapy for metastatic breast cancer. Prior immunotherapy and/or monoclonal antibody therapy are acceptable. Prior treatments must have been discontinued at least 30 days prior to start of study treatment and all related toxicities must have resolved to Grade 1 or less.

  9. Prior neoadjuvant or adjuvant chemotherapy, if given, must have been completed at least 6 months before randomization with all related toxicities resolved, and documented evidence of disease progression per RECIST 1.1 guidelines is required.

    a. If prior neoadjuvant or adjuvant chemotherapy contained taxane, gemcitabine, or platinum agents, the treatment must have completed at least 12 months before randomization

  10. Prior radiotherapy must have completed before randomization, with full recovery from acute radiation side effects. At least one measurable lesion must be completely outside the radiation portal or there must be unequivocal radiologic or clinical exam proof of progressive disease within the radiation portal, in accordance with RECIST 1.1 guidelines
  11. At least 30 days from major surgery before randomization, with full recovery
  12. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

  13. Subject has the following blood counts at screening:

    • Absolute Neutrophil Count (ANC) ≥ 1500/mm^2 ;
    • Platelets ≥ 100,000/mm^2 ;
    • Hemoglobin (Hgb) ≥ 9 g/dL

  14. Subject has the following blood chemistry levels at screening:

    • Aspartate aminotransferase (AST) Serum glutamic-oxaloacetic transaminase (SGOT), Alanine Aminotransferase (ALT ) Serum Glutamic Pyruvate Transaminase (SGPT) ≤ 2.5 x upper limit of normal range (ULN); if hepatic metastases present ≤ 5.0 x ULN
    • Total serum bilirubin ≤ ULN; or total bilirubin ≤ 3.0 × ULN with direct bilirubin within normal range in subjects with documented Gilbert's Syndrome
    • Creatinine clearance > 60 mL/min (by Cockcroft-Gault)

  15. Females of child-bearing potential [defined as a sexually mature women who (1) have not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months)] must:

    • Demonstrate a negative serum pregnancy test result at screening (performed by central lab) confirmed by local negative urine pregnancy dipstick within 72 hours prior to the first dose of IP); pregnancy test with sensitivity of at least 25 mIU/mL; and
    • Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis) or agree to use, and be able to comply with, two physician approved effective contraception methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) without interruption for 28 days or longer as required by local guidelines, prior to starting study drug, during the study therapy (including dose interruptions), and for 28 days after discontinuation of the study or longer as required by local guidelines
  16. Females must abstain from breastfeeding starting at randomization, during study participation and for 28 days or longer as required by local guidelines, after IP discontinuation
  17. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted
  18. Able to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

  1. Male subjects
  2. Concurrent chemotherapy or any other anti tumor therapy for breast cancer. Prior immunotherapy & monoclonal antibody therapy are acceptable.
  3. Subjects who received prior cytotoxic chemotherapy after incomplete resection of locoregional recurrent disease
  4. History of, or known current evidence of brain metastasis, including leptomeningeal involvement.
  5. Subjects with bone as the only site of metastatic disease
  6. Subjects with regional lymph node as the only site of metastatic disease
  7. Serious intercurrent medical or psychiatric illness, including serious active infection
  8. History of class II-IV congestive heart failure or myocardial infarction within 6 months of randomization
  9. History of other primary malignancy in the last 5 years prior to randomization. Subjects with prior breast cancer history are eligible, however, the most recently obtained biopsy must demonstrate triple negative disease (source documented). Subjects with prior history of in situ cancer or basal or localized squamous cell skin cancer are eligible.
  10. Subjects with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple uncontrolled or unstable allergies which, in the opinion of the investigator, may lead to serious complications
  11. Peripheral neuropathy Grade ≥ 2 by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0
  12. Subjects who have received an investigational product within the previous 4 weeks prior to randomization
  13. Subject is currently enrolled, or will enroll in a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study
  14. Pregnant or nursing women
  15. Subjects with prior hypersensitivity to nab-paclitaxel, gemcitabine, carboplatin or any other platin, or nucleoside analogue agents
  16. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
  17. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if she were to participate in the study
  18. Any condition that confounds the ability to interpret data from the study
  19. History of seropositive human immunodeficiency virus (HIV)
  20. Subjects who are receiving immunosuppressive or myelosuppressive medications that would, in the opinion of the investigator, increase the risk of serious neutropenic complications

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: nab-Paclitaxel plus Gemcitabine
Treatment Arm A: nab-Paclitaxel 125 mg/m^2 by intravenous (IV) administration over 30 minutes, followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 of each 21-day cycle by IV administration over 30 minutes
Arzneimittel: nab-Paclitaxel
nab-Paclitaxel 125 mg/m^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.
Andere Namen:
  • Abraxane
Arzneimittel: Gemcitabine
Gemcitabine 1000 mg/m^2 on Days 1 and 8 of each 21-day treatment cycle.
Andere Namen:
  • Gemzar
Experimental: nab-Paclitaxel plus Carboplatin
Treatment Arm B: nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin at an Area Under the Curve (AUC) of 2 on Days 1 and 8 of each 21-day cycle by IV administration
Arzneimittel: nab-Paclitaxel
nab-Paclitaxel 125 mg/m^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.
Andere Namen:
  • Abraxane
Arzneimittel: Carboplatin
Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration
Andere Namen:
  • Paraplatin AQ
  • Paraplatin,
Aktiver Komparator: Gemcitabine plus Carboplatin
Treatment Arm C: Gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin AUC 2 on Days 1 and 8 of each 21-day cycle by IV administration
Arzneimittel: Gemcitabine
Gemcitabine 1000 mg/m^2 on Days 1 and 8 of each 21-day treatment cycle.
Andere Namen:
  • Gemzar
Arzneimittel: Carboplatin
Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration
Andere Namen:
  • Paraplatin AQ
  • Paraplatin,

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment.
Zeitfenster: From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C
PFS was defined as the time from the date of randomization to the date of disease progression or death from any cause on or prior to the data cutoff date for the statistical analysis, whichever occurred earlier. Tumor responses were assessed every 6 weeks using, Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and defined as: Complete response (CR) is the disappearance of all target lesions; Partial response (PR) occurs when at least a 30% decrease in the sum of diameters of target lesions from baseline; Stable disease is neither sufficient shrinkage to qualify for a PR nor sufficient increase of lesions to qualify for Progressive disease (PD); Progressive Disease- is at least a 20% increase in the sum of diameters of target lesions from nadir.
From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of Participants With an Objective Complete or Partial Overall Response by Investigator Assessment.
Zeitfenster: Disease response was assessed every 6 weeks; from date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C
Percentage of participants with an Objective Complete or Partial Overall Response according to RECIST 1.1 and defined as: Complete response-disappearance of all target lesions; partial response at least a 30% decrease in the sum of diameters of target lesions from baseline; stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for Progressive disease (PD)• Progressive Disease- At least a 20% increase in the sum of diameters of target lesions from nadir.
Disease response was assessed every 6 weeks; from date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C
Percentage of Participants Who Initiated Cycle 6 Receiving Doublet Combination Therapy
Zeitfenster: Cycle 6
The percentage of participants who initiated Cycle 6 receiving doublet combination therapy regardless of the need for dose modifications.
Cycle 6
Kaplan-Meier Estimates of Overall Survival
Zeitfenster: From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C
Overall survival was defined as the time from the date of randomization to the date of death (from any cause).
From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Zeitfenster: From randomization through to 28 days after the last dose of IP; up to data cut off date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C
Treatment-emergent adverse events (TEAEs) were defined as any AEs that began or worsened with the onset date on or after the date of the first dose of IP through 28 days after the last dose. A serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was graded based on the participant's symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity as follows: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death.
From randomization through to 28 days after the last dose of IP; up to data cut off date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C
Percentage of Participants Experiencing Dose Modifications (Reductions and Interruptions)
Zeitfenster: From randomization through to 28 days after the last dose of IP; up to data-cut off of date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C
The number of participants with dose modifications occurring during the treatment period. Dose reductions and interruptions are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.
From randomization through to 28 days after the last dose of IP; up to data-cut off of date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C
Percentage of Participants Who Discontinued From All Study Treatment Due to TEAEs
Zeitfenster: From randomization through to 28 days after the last dose of IP; up to data-cut off of date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C
Treatment-emergent adverse events (TEAEs) were defined as any AEs that begin or worsen with an onset date on or after the date of the first dose of IP through 28 days after the last dose.
From randomization through to 28 days after the last dose of IP; up to data-cut off of date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Celgene

Ermittler

  • Studienleiter: Ileana Elias, M.D., Celgene Corporation

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

26. September 2013

Primärer Abschluss (Tatsächlich)

28. Oktober 2016

Studienabschluss (Tatsächlich)

28. Oktober 2016

Studienanmeldedaten

Zuerst eingereicht

17. Juni 2013

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

17. Juni 2013

Zuerst gepostet (Schätzen)

19. Juni 2013

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

21. Februar 2019

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

19. Februar 2019

Zuletzt verifiziert

1. Februar 2019

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • ABI-007-MBC-001
  • 2013-000113-20 (EudraCT-Nummer)

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren